Background And Aims: Over the last decade, treatment options for moderate-to-severe ulcerative colitis (UC) have expanded. However, comparative studies between these agents are limited, especially among biologic-naïve patients. We aimed to compare the persistence, effectiveness and safety of tofacitinib and vedolizumab as the first advanced treatment for patients with UC.
View Article and Find Full Text PDFBackground: Healthcare provider leadership programs represent an intervention opportunity to support advancement of the national system of care and an evaluation of their program impacts is needed. Between 2016 and 2023, the Robert Wood Johnson Foundation (RWJF) funded Clinical Scholars (CS), a three-year equity-centered leadership training program for US healthcare providers. CS recruited participants (referred to as Fellows) in cohorts and engaged them as members of interprofessional teams to transform their careers and the health of their communities.
View Article and Find Full Text PDFMucormycosis (zygomycosis) is a severe and often fatal mycotic infection affecting primarily immunocompromised individuals. A 61-year-old female with type 2 diabetes mellitus and end-stage renal disease developed septic shock in association with mucormycosis. Despite antifungal treatment with liposomal amphotericin B, the patient's condition rapidly deteriorated, leading to death within 48 hours.
View Article and Find Full Text PDF